Money
Filter News
Found 62,250 articles
-
City of Hope announced plans to build a new comprehensive cancer campus at FivePoint Gateway in Orange County. As part of that plan, it will invest more than $1 billion into the project.
-
The deal comes as Dermira plans to initiate Phase III studies in the U.S.
-
The company will focus on chemoproteomics, which it calls a way of interrogating proteins in living systems. This allows them to identify potential new binding targets on proteins, which will allow the development of small-molecule drugs.
-
A recent list of the top 10 most expensive drugs marketed in the United States shows each of them has a list price of more than half a million dollars annually.
-
Sareum Holdings plc: Placing to raise £513,200 to progress proprietary TYK2/JAK1 programmes in preclinical development
6/25/2019
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announces that it has raised £513,200, before expenses, through a placement by Hybridan LLP of 128,300,000 new ordinary shares of 0.025p each in the capital of the Company (the "Placing Shares") at 0.4p per share.
-
The birth of RegTech
6/25/2019
We first witnessed the emergence of RegTech shortly after the economic plunge of 2008. The financial disaster spurred an increase in regulation in the finance and banking industries, and as a result, companies began to shell out billions in compliance costs.
-
Odonate Therapeutics Announces Public Offering of Shares of Common Stock
6/25/2019
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has commenced an underwritten public offering of approximately $100 million of shares of its common stock.
-
InterVene Raises $15 Million in Series B Funding for First Catheter-Based System to Correct Deep Vein Valve Failure
6/25/2019
InterVene Inc. today announced it has raised $15 million in a Series B financing round.
-
NORD Awards Ten New Grants in Eight Disease States for Rare Disease Research
6/25/2019
The National Organization for Rare Disorders® (NORD), the leading independent nonprofit organization representing the 25-30 million Americans living with rare diseases, has announced ten new grants as part of its Rare Disease Research Grant Program, which celebrates its 30th anniversary in 2019.
-
Frontier Medicines launches with $67 million to develop novel medicines that drug the "undruggable" targets driving human disease
6/25/2019
Frontier Medicines today announced the closing of a Series A Preferred Stock financing round of $67 million led by Deerfield Management, Droia Oncology Ventures and MPM Capital, with participation from DCVC Bio (an affiliated fund of DCVC), RA Capital Management and other investors.
-
Oska Wellness Secures $5.5 Million Private Investment from Individuals Key to Medical Industry
6/25/2019
Oska Wellness, a pioneer of technology-driven wellness solutions, has raised $5.5 million in a first round of funding as consumers and the medical industry search for drug-free alternatives to manage pain.
-
S&P and Fitch Upgrade CNO Financial Group
6/25/2019
Two ratings agencies, S&P and Fitch recently upgraded the credit ratings of CNO Financial Group (NYSE: CNO).
-
Fusion Robotics™ Closes Financing to Advance Spinal Robotics Platforms
6/25/2019
Fusion Robotics™ today announced the closing of a financing round for an undisclosed amount with lead investment by Alex Lukianov (Lukpartners, LLC) and Kevin Foley, MD. T
-
Joerns Healthcare Seeking To Eliminate Debt With Restructuring Plan
6/25/2019
The company is seeking court approval of a restructuring plan that is supported by the majority of its lenders and noteholders.
-
Recondo Technology, Generating 16M Annual Patient Estimates, Issues Statement on Trump Administration's Executive Order to Promote Healthcare Price Transparency
6/25/2019
Industry leader with 12 years of experience in automated patient price estimates provides guidance on how hospitals can comply in a way that improves patient satisfaction and pre-service collections.
-
“Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene,” the company stated. “The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis.”
-
Catalent Announces Pricing of Private Offering of Senior Unsecured Notes Due 2027
6/24/2019
Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of $500.0 million in aggregate principal amount of 5.00% senior unsecured notes due 2027 (the “Notes”) at par.
-
Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair
6/24/2019
Former Biogen Idec executive to bring additional strategic expertise to Sutro's Board
-
The Medicines Company Announces Launch of Public Offering of Common Stock
6/24/2019
The Company expects to use the net proceeds of the offering to fund its development of inclisiran and for general corporate purposes.
-
Alzheimer's Foundation, Congressmen Suozzi, King Announce New Legislation to Increase Funding to Fight Alzheimer's
6/24/2019
Congressmen Suozzi and King, working with AFA, are sponsoring the legislation to create the Alzheimer's Research and Caregiving Trust Fund to provide additional funding to federal Alzheimer's research and caregiver support services.